EP1477175A1 — Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
Assigned to Ono Pharmaceutical Co Ltd · Expires 2004-11-17 · 21y expired
What this patent protects
Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as …
USPTO Abstract
Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc. ), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc .), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc. ), diabetes, shock, head trauma, renal failure, hyperalgesia, etc . Moreover, these compounds are useful as agents against retroviruses (HIV etc. ), sensitizers in treating cancer and immunosuppressants.
Drugs covered by this patent
- Lynparza (olaparib) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.